PTC Therapeutics Gets FDA Priority Review of Upstaza Gene Therapy

Dow Jones05-14

By Colin Kellaher

PTC Therapeutics has won U.S. Food and Drug Administration priority review for its application seeking approval of its Upstaza gene therapy for the treatment of AADC deficiency, a rare genetic disorder.

The Warren, N.J., biopharmaceutical company on Tuesday said the FDA set a target action date of Nov. 13 for a decision on Upstaza, which won European Union approval in 2022 as the first gene therapy for AADC deficiency, which typically causes severe disability and suffering from the first months of life.

The FDA grants priority review to medicines that have the potential to provide significant improvements in the treatment of a serious disease, and the designation shortens the review period.

Write to Colin Kellaher at colin.kellaher@wsj.com

(END) Dow Jones Newswires

May 14, 2024 07:57 ET (11:57 GMT)

Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.

Comments

We need your insight to fill this gap

Leave a comment

{"i18n":{"language":"en_US"},"isChannel":false,"data":{"share":"https://ttm.financial/m/news/2435059737?lang=en_US&edition=fundamental","thumbnail":"","is_english":true,"pubTime":"2024-05-14 19:57","share_image_url":"https://static.laohu8.com/e9f99090a1c2ed51c021029395664489","id":"2435059737","market":"other","top_or_hot":-1,"title":"PTC Therapeutics Gets FDA Priority Review of Upstaza Gene Therapy","media":"Dow Jones","content":"<font class=\"NormalMinus1\" face=\"Arial\">\n<pre>\n \n</pre>\n<p>\n  By Colin Kellaher \n</p>\n<pre>\n \n</pre>\n<p>\n  PTC <a href=\"https://laohu8.com/S/LENZ\">Therapeutics</a> has won U.S. Food and Drug Administration priority review for its application seeking approval of its Upstaza gene therapy for the treatment of AADC deficiency, a rare genetic disorder. \n</p>\n<p>\n  The Warren, N.J., biopharmaceutical company on Tuesday said the FDA set a target action date of Nov. 13 for a decision on Upstaza, which won European Union approval in 2022 as the first gene therapy for AADC deficiency, which typically causes severe disability and suffering from the first months of life. \n</p>\n<p>\n  The FDA grants priority review to medicines that have the potential to provide significant improvements in the treatment of a serious disease, and the designation shortens the review period. \n</p>\n<pre>\n \n</pre>\n<p>\n  Write to Colin Kellaher at colin.kellaher@wsj.com \n</p>\n<pre>\n \n</pre>\n<p>\n  (END) Dow Jones Newswires\n</p>\n<p>\n  May 14, 2024 07:57 ET (11:57 GMT)\n</p>\n<p>\n  Copyright (c) 2024 Dow Jones &amp; Company, Inc.\n</p>\n</font>","source":null,"html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>PTC Therapeutics Gets FDA Priority Review of Upstaza Gene Therapy</title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 11px; color: #7E829C; margin: 0;line-height: 11px;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\nPTC Therapeutics Gets FDA Priority Review of Upstaza Gene Therapy\n</h2>\n\n<h4 class=\"meta\">\n\n\n2024-05-14 19:57 GMT+8&nbsp;&nbsp;&nbsp;<a href=https://dowjonesnews.com/newdjn/logon.aspx?AL=N><strong>Dow Jones</strong></a>\n\n\n</h4>\n\n</header>\n<article>\n<div>\n<p>By Colin Kellaher \n\n\n \n\n\n  PTC Therapeutics has won U.S. Food and Drug Administration priority review for its application seeking approval of its Upstaza gene therapy for the treatment of AADC ...</p>\n\n<a href=\"https://dowjonesnews.com/newdjn/logon.aspx?AL=N\">Source Link</a>\n\n</div>\n\n\n</article>\n</div>\n</body>\n</html>\n","isBrief":false,"type":0,"news_type":1,"symbol":"LU0889565916.HKD","symbol_name":"FRANKLIN BIOTECHNOLOGY DISCOVERY \"A\" (HKD) ACC","start_time":0,"source_url":"https://dowjonesnews.com/newdjn/logon.aspx?AL=N","article_id":"2435059737","we_media_id":"106","thumbnails":[],"rights":null,"url":"https://stock-news.laohu8.com/highlight/detail?id=2435059737","pubTimestamp":1715687820,"sourceInfo":null,"weMediaInfo":{"media_name":"Dow Jones","introduction":"Dow Jones publishes the world’s most trusted business news and financial information in a variety of media.","home_visible":0,"id":"106","head_image":"https://static.tigerbbs.com/150f88aa4d182df19190059f4a365e99"},"summary":"PTC Therapeutics has won U.S. Food and Drug Administration priority review for its application seeking approval of its Upstaza gene therapy for the treatment of AADC deficiency, a rare genetic disorder.The Warren, N.J., biopharmaceutical company on Tuesday said the FDA set a target action date of Nov. 13 for a decision on Upstaza, which won European Union approval in 2022 as the first gene therapy for AADC deficiency, which typically causes severe disability and suffering from the first months of life.The FDA grants priority review to medicines that have the potential to provide significant improvements in the treatment of a serious disease, and the designation shortens the review period.","collect":0,"end_time":0,"defaultTopTitle":"","property":[],"viewcount":null,"language":"en","relate_stocks":{"LU0889565916.HKD":"FRANKLIN BIOTECHNOLOGY DISCOVERY \"A\" (HKD) ACC","LU1923623000.USD":"Natixis Thematics AI & Robotics Fund R/A USD","BK4585":"ETF&股票定投概念","PTC":"PTC Inc.","LU1951198990.SGD":"Natixis Thematics AI & Robotics Fund H-R/A SGD-H","BK4139":"生物科技","BK4576":"AR","LU0320765992.SGD":"FTIF - Franklin Biotechnology Discovery A Acc SGD","BK4588":"碎股","PTCT":"PTC Therapeutics Inc.","LU1951200564.SGD":"Natixis Thematics AI & Robotics Fund R/A SGD","LU0109394709.USD":"富兰克林生物科技新领域基金A (acc)","BK4023":"应用软件","BK4554":"元宇宙及AR概念"},"translate_title":"PTC治疗获得FDA优先审查Upstaza基因治疗","themeId":null,"isJumpTheme":false,"ttsUrl":null,"symbols_score_info":{"PTC":1,"PTCT":1},"content_text":"By Colin Kellaher \n\n\n \n\n\n  PTC Therapeutics has won U.S. Food and Drug Administration priority review for its application seeking approval of its Upstaza gene therapy for the treatment of AADC deficiency, a rare genetic disorder. \n\n\n  The Warren, N.J., biopharmaceutical company on Tuesday said the FDA set a target action date of Nov. 13 for a decision on Upstaza, which won European Union approval in 2022 as the first gene therapy for AADC deficiency, which typically causes severe disability and suffering from the first months of life. \n\n\n  The FDA grants priority review to medicines that have the potential to provide significant improvements in the treatment of a serious disease, and the designation shortens the review period. \n\n\n \n\n\n  Write to Colin Kellaher at colin.kellaher@wsj.com \n\n\n \n\n\n  (END) Dow Jones Newswires\n\n\n  May 14, 2024 07:57 ET (11:57 GMT)\n\n\n  Copyright (c) 2024 Dow Jones & Company, Inc.","kind":null,"is_publish_news":null,"is_publish_highlight":null,"is_publish_live":null,"is_publish_wemedia":null,"editions":null,"symbols":[],"gpt_button":1},"commentList":[],"isCommentEnd":true,"newsSizeData":{"likeSize":0,"commentSize":0,"repostSize":0,"favoriteSize":0,"likeStatus":false,"favoriteStatus":false},"APP":{"userAgent":"Mozilla/5.0 AppleWebKit/537.36 (KHTML, like Gecko; compatible; ClaudeBot/1.0; +claudebot@anthropic.com)","isDev":false,"isTTM":true,"deviceId":"web-server-community-laohu8-v3","version":"4.22.5","shortVersion":"4.22.5","platform":"web","vendor":"web","appName":"ttm","isIOS":false,"isAndroid":false,"isTiger":false,"isTHS":false,"isWeiXin":false,"isWeiXinMini":false,"isWeiBo":false,"isQQ":false,"isBaiduSwan":false,"isBaiduBox":false,"isDingTalk":false,"isToutiao":false,"isOnePlus":false,"isHuaWei":false,"isXiaomi":false,"isXiaomiWebView":false,"isOppo":false,"isVivo":false,"isSamsung":false,"isMobile":false},"href":"/m/news/2435059737"}